CoChat

Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus

Triplitt, Curtis, DeFronzo, Ralph A · 2006 · Expert Review of Endocrinology & Metabolism
Cited by 25

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Exenatide is the first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Mechanistically, it mimics several of the glucoregulatory effects of glucagon-like peptide-1 including: 1) glucose-dependent insulin secretion via the glucose-dependent glucagon-like peptide-1 pancreatic receptor; 2) suppression of elevated plasma glucagon levels; 3) reduction in the rate of appearance of glucose into the systemic circulation by normalizing the accelerated rate of gastric emptying often present in Type 2 diabetes mellitus; 4) reduction of food intake, which in turn promotes weight loss; 5) stimulation of the glucagon-like peptide-1 receptor. A1C reductions of approximately 1% can be expected with a baseline A1C of 8.0–8.5%. Exenatide significantly reduces postprandial glucose levels, while having only a modest effect on the fasting plasma glucose. Hypoglycemic risk is no different to placebo when combined with metformin or a thiazolidinediones, but is higher when combined with a sulfonylurea, possibly requiring reduction in the sulfonylurea dose. Exenatide may cause gastrointestinal side effects upon initiation, which usually lessen over time. Gastrointestinal side effects can be reduced by starting exenatide 5 µg subcutaneously twice daily before meals; if tolerated, titration to 10 µg twice daily before meals at 1 month may further improve glycemia and weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/17446651.1.3.329

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 25

Metadata

Authors
Triplitt, C., & DeFronzo, R. A.
Venue
Expert Review of Endocrinology & Metabolism
Published
2006-05
Volume
1
Issue
3
Pages
329-341
ISSN
  • 1744-6651 (ISSN-L)
  • 1744-8417
OpenAlex
W2141514017
Cited by
25
References
28
FWCI
0.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1586/17446651.1.3.329
The paper
Triplitt, C., & DeFronzo, R. A. (2006). Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism. https://doi.org/10.1586/17446651.1.3.329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.